News | October 03, 2025
Genmab to acquire Merus for $ 8 billion
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
Subscribe To Our Newsletter & Stay Updated